These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction.
    Author: Yazaki Y, Muhlestein JB, Carlquist JF, Bair TL, Horne BD, Renlund DG, Anderson JL.
    Journal: J Card Fail; 2004 Aug; 10(4):316-20. PubMed ID: 15309698.
    Abstract:
    BACKGROUND: A recent retrospective study suggested that the adenosine monophosphate deaminase (AMPD)-1 gene variant C34T predicts outcome in heart failure patients. This variant might lead to ischemic preconditioning by increasing tissue adenosine. We tested whether the survival benefit of C34T occurs preferentially in the setting of ischemic left ventricular dysfunction. METHODS AND RESULTS: A consecutive cohort of patients (n=390) with left ventricular ejection fraction <40% was evaluated. In the ischemic patient subgroup (n=210) multivariate analysis identified AMPD1 T allele carriage (hazard ratio=0.43, confidence interval=0.20-0.94, P=.035) as an independent predictor of transplant-free cardiovascular survival. No benefit was found in the nonischemic group although the number of events was too small to reliably exclude a benefit by genotype. CONCLUSION: The AMPD1 C34T polymorphism influences transplant-free cardiovascular survival in the setting of ischemic left ventricular dysfunction.
    [Abstract] [Full Text] [Related] [New Search]